KYTHERA Biopharmaceuticals (FRA:KYT) Forward PE Ratio : 0.00 (As of May. 29, 2024)

View and export this data going back to . Start your Free Trial

What is KYTHERA Biopharmaceuticals Forward PE Ratio?

KYTHERA Biopharmaceuticals's Forward PE Ratio for today is 0.00.

KYTHERA Biopharmaceuticals's PE Ratio without NRI for today is 0.00.

KYTHERA Biopharmaceuticals's PE Ratio for today is 0.00.

KYTHERA Biopharmaceuticals Forward PE Ratio Historical Data

The historical data trend for KYTHERA Biopharmaceuticals's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KYTHERA Biopharmaceuticals Forward PE Ratio Chart

KYTHERA Biopharmaceuticals Annual Data

Trend

Forward PE Ratio

KYTHERA Biopharmaceuticals Quarterly Data

Forward PE Ratio

Competitive Comparison of KYTHERA Biopharmaceuticals's Forward PE Ratio

For the Drug Manufacturers - General subindustry, KYTHERA Biopharmaceuticals's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

KYTHERA Biopharmaceuticals's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, KYTHERA Biopharmaceuticals's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where KYTHERA Biopharmaceuticals's Forward PE Ratio falls into.

KYTHERA Biopharmaceuticals Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.

KYTHERA Biopharmaceuticals (FRA:KYT) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .

KYTHERA Biopharmaceuticals Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of KYTHERA Biopharmaceuticals's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

KYTHERA Biopharmaceuticals (FRA:KYT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » KYTHERA Biopharmaceuticals Inc (FRA:KYT) » Definitions » Forward PE Ratio

Traded in Other Exchanges

N/A

Address

Website

http://www.kytherabiopharma.com

KYTHERA Biopharmaceuticals Inc was incorporated in Delaware in June 2004 under the name Dermion, Inc. It commenced operations in August 2005, and it changed its name to AESTHERx, Inc. In July 2006, it changed its name to KYTHERA Biopharmaceuticals, Inc. It is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. The Company's objective is to develop first-in-class, prescription aesthetic products using an approach that relies on the scientific rigor of biotechnology to address unmet needs in the rapidly-growing market for aesthetic medicine. The Company's initial focus is on the facial aesthetics market, which comprises the majority of the aesthetic medicine market. The Company's product candidate, ATX-101, is a potential first-in-class, injectable drug in late stage clinical development for the reduction of submental fat, which commonly presents as an undesirable double chin. Based on clinical trials conducted to date, ATX-101 has exhibited significant, meaningful and long-lasting results in the reduction of submental fat.

KYTHERA Biopharmaceuticals (FRA:KYT) Headlines

No Headlines